Misplaced Pages

Potrasertib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 01:05, 30 December 2024 editJosve05a (talk | contribs)Autopatrolled, Extended confirmed users, New page reviewers, Pending changes reviewers, Rollbackers155,244 editsm clean up, added orphan tagTag: AWB← Previous edit Revision as of 12:25, 30 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,879 edits ceNext edit →
Line 110: Line 110:
| specific_rotation = | specific_rotation =
}} }}
'''Potrasertib''' is an ] that is being evaluated for the treatment of advanced solid tumors. It is oral inhibitor of ] kinase, a key regulator of ]s, currently being developed by IMPACT Therapeutics.<ref>{{cite web | title = IMP 7068 | url = https://adisinsight.springer.com/drugs/800058368 | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref><ref name="pmid38231277">{{cite journal | vauthors = Wang Z, Li W, Li F, Xiao R | title = An update of predictive biomarkers related to WEE1 inhibition in cancer therapy | journal = Journal of Cancer Research and Clinical Oncology | volume = 150 | issue = 1 | pages = 13 | date = January 2024 | pmid = 38231277 | pmc = 10794259 | doi = 10.1007/s00432-023-05527-y }}</ref> '''Potrasertib''' is an ] that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is oral inhibitor of ] kinase, a key regulator of ]s.<ref>{{cite web | title = IMP 7068 | url = https://adisinsight.springer.com/drugs/800058368 | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref><ref name="pmid38231277">{{cite journal | vauthors = Wang Z, Li W, Li F, Xiao R | title = An update of predictive biomarkers related to WEE1 inhibition in cancer therapy | journal = Journal of Cancer Research and Clinical Oncology | volume = 150 | issue = 1 | pages = 13 | date = January 2024 | pmid = 38231277 | pmc = 10794259 | doi = 10.1007/s00432-023-05527-y }}</ref>


== References == == References ==

Revision as of 12:25, 30 December 2024

This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (December 2024)

Pharmaceutical compound
Potrasertib
Clinical data
Other namesIMP7068
Identifiers
IUPAC name
  • 7-(2,6-dichlorophenyl)-12-anilino]-2,5,7,11,13-pentazatricyclotrideca-1(13),5,9,11-tetraen-8-one
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H30Cl2N8O
Molar mass565.50 g·mol
3D model (JSmol)
SMILES
  • C1CN(C(N1C)C)C2=C(C=C(C=C2)NC3=NC=C4C(=N3)N5CCN=C5N(C4=O)C6=C(C=CC=C6Cl)Cl)C
InChI
  • InChI=InChI=1S/C28H30Cl2N8O/c1-16-12-19(8-9-23(16)36-14-17(2)35(4)18(3)15-36)33-27-32-13-20-25(34-27)37-11-10-31-28(37)38(26(20)39)24-21(29)6-5-7-22(24)30/h5-9,12-13,17-18H,10-11,14-15H2,1-4H3,(H,32,33,34)/t17-,18+
  • Key:BNVDJVMTLDUCGH-HDICACEKSA-N

Potrasertib is an investigational new drug that is being evaluated by IMPACT Therapeutics for the treatment of advanced solid tumors. It is oral inhibitor of WEE1 kinase, a key regulator of cell cycle checkpoints.

References

  1. "IMP 7068". AdisInsight. Springer Nature Switzerland AG.
  2. Wang Z, Li W, Li F, Xiao R (January 2024). "An update of predictive biomarkers related to WEE1 inhibition in cancer therapy". Journal of Cancer Research and Clinical Oncology. 150 (1): 13. doi:10.1007/s00432-023-05527-y. PMC 10794259. PMID 38231277.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Potrasertib: Difference between revisions Add topic